Logo

ENOV

Enovis Corporation

ENOV

Enovis Corporation • NYSE
$30.27 ▼ -0.13% (-0.04)
Market Cap $1.73 B
52w High $49.75
52w Low $25.47
Dividend Yield 0%
P/E -1.24
Volume 233.10K
Outstanding Shares 57.17M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $548.912M ▼ $899.786M ▲ $-571.146M ▼ -104.051% ▼ $0 ▲ $-477.817M ▼
Q2-2025 $564.545M ▲ $351.493M ▼ $-36.739M ▲ -6.508% ▲ $-0.64 ▲ $55.191M ▲
Q1-2025 $558.834M ▼ $378.998M ▼ $-55.966M ▲ -10.015% ▲ $-0.99 ▲ $23.274M ▲
Q4-2024 $560.975M ▲ $972.267M ▲ $-703.337M ▼ -125.378% ▼ $-12.05 ▼ $-590.255M ▼
Q3-2024 $505.222M $318.196M $-31.521M -6.239% $-0.57 $39.692M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $33.617M ▼ $4.433B ▼ $2.41B ▼ $2.021B ▼
Q2-2025 $44.074M ▲ $5.021B ▲ $2.44B ▲ $2.578B ▼
Q1-2025 $38.46M ▼ $4.875B ▲ $2.255B ▲ $2.618B ▲
Q4-2024 $48.167M ▲ $4.719B ▼ $2.154B ▼ $2.562B ▼
Q3-2024 $35.425M $5.55B $2.217B $3.33B

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-570.913M ▼ $82.576M ▲ $-56.06M ▼ $-36.907M ▼ $-10.457M ▼ $29.085M ▲
Q2-2025 $-36.646M ▲ $47.769M ▲ $-49.801M ▲ $6.231M ▼ $5.614M ▲ $3.4M ▲
Q1-2025 $-55.705M ▲ $-1.596M ▼ $-60.519M ▼ $51.191M ▲ $-9.707M ▼ $-44.858M ▼
Q4-2024 $-703.2M ▼ $88.33M ▲ $-57.884M ▲ $-20.08M ▼ $8.369M ▲ $35.138M ▲
Q3-2024 $-31.262M $53.557M $-58.421M $-148K $-3.626M $2.368M

Revenue by Products

Product Q2-2021Q3-2021Q4-2021Q1-2022
Fabrication Technology
Fabrication Technology
 $630.00M ▲$610.00M ▼$620.00M ▲$650.00M ▲
Medical Technology
Medical Technology
 $360.00M ▲$360.00M ▲$400.00M ▲$380.00M ▼

Five-Year Company Overview

Income Statement

Income Statement Revenue has grown at a healthy pace over the past five years, showing that demand for Enovis products is moving in the right direction. However, profits have not kept up with this growth. Operating profit has been negative in most recent years, and the latest year shows a sizable loss at both the operating and net income level. This suggests heavy spending on acquisitions, integration, and innovation, along with possibly higher costs and restructuring. In short, the business is scaling its sales base but is still in an investment and transition phase from a profitability standpoint, with earnings volatility and pressure in the most recent year standing out as a key risk factor.

Balance Sheet

Balance Sheet The balance sheet shows a company that still has a solid equity base but is taking on more financial risk to support its strategy. Total assets have edged up, but cash on hand is now quite low compared with earlier years, meaning less of a cash cushion. Debt was reduced steadily for several years and then jumped sharply in the latest year, likely tied to a major acquisition, which increases leverage and interest obligations. Shareholders equity remains positive but has drifted down from prior peaks, reflecting recent losses. Overall, the balance sheet can support growth, but rising debt and limited cash make disciplined execution and cash generation increasingly important.

Cash Flow

Cash Flow Cash flow from operations has generally been positive, indicating that the core business can generate cash, even though the amounts are modest relative to the companys size and growth ambitions. Free cash flow has been uneven, swinging between positive and negative as capital spending has stepped up in recent years. The latest year shows that higher investment outlays are outpacing the cash coming in, which fits with an aggressive growth and innovation strategy but leaves less room for error. Sustained, stronger operating cash flow will be important to comfortably fund ongoing R&D, integration, and debt service without relying too heavily on external financing.

Competitive Edge

Competitive Edge Enovis has carved out a differentiated position in orthopedic care rather than being a generic industrial company. It benefits from well-known brands such as DonJoy in bracing, a broad portfolio that covers the full patient journey from surgery through rehabilitation, and a growing presence in reconstructive implants. Its digital tools and workflow software create a sticky ecosystem that can be hard for hospitals and clinics to replace once embedded. At the same time, the company faces intense competition from large, well-capitalized medtech players, and success depends on persuading surgeons and care centers to adopt its newer platforms. The strategy of being a one-stop, technology-enabled orthopedic partner is a strength, but execution against larger incumbents and smooth integration of acquisitions remain key challenges.

Innovation and R&D

Innovation and R&D Innovation is clearly at the center of Enovis strategy. The company is pushing advanced technologies such as the ARVIS augmented reality surgery system, new implant designs, and connected digital platforms that help manage workflows and patient engagement. Its heritage in bracing is being enhanced with smart materials and proprietary hinge technologies, while acquisitions have added capabilities in 3D-printed implants and advanced shoulder, hip, and foot and ankle solutions. This innovation focus can deepen customer relationships and support premium positioning but also requires ongoing heavy investment and careful commercialization. The future payoff hinges on broad clinical adoption, regulatory and reimbursement support, and the companys ability to integrate these technologies into a cohesive, user-friendly platform for surgeons and providers.

Summary

Enovis is in the middle of a strategic transformation toward becoming a high-growth, innovation-led medtech and orthopedic specialist. Revenue growth and a strengthening product and technology portfolio show clear progress on that front. At the same time, profitability has been weak and recently deteriorated, debt has increased, and free cash flow has been inconsistent, all of which underscore that this transformation is still underway and carries meaningful execution risk. The companys competitive edge lies in its combination of recognized brands, enabling technologies, and integrated software and hardware offerings, particularly in reconstructive surgery and orthopedic bracing. Going forward, the crucial questions are whether Enovis can convert its innovation pipeline and acquisitions into durable, profitable growth and whether it can do so while stabilizing earnings, strengthening cash generation, and managing its higher leverage.

NEWS

November 6, 2025 · 6:01 AM UTC

Enovis Announces Third Quarter 2025 Results

Read more

October 24, 2025 · 4:11 PM UTC

Enovis announces webcast and conference call for Third Quarter 2025 Results and participation in upcoming investor conferences

Read more

October 8, 2025 · 8:15 AM UTC

Enovis completes sale of its Dr. Comfort Footcare Solutions business for proceeds of up to $60 million

Read more

September 8, 2025 · 4:05 PM UTC

Enovis Corporation Announces Time Change for Presentation at Baird 2025 Global Healthcare Conference

Read more